Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis.

Julia JeckFlorian JakobsMelina S KurteOliver Andreas CornelyFlorian Kron

Published in: JAC-antimicrobial resistance (2023)

Treatment of candidiasis is cost intensive due to increased hospital LOS. The ICU LOS reduction rezafungin showed in STRIVE would lead to sustainable cost savings.

Keyphrases

healthcare
public health
candida albicans
intensive care unit
emergency department
mechanical ventilation
social media
health information
smoking cessation
health promotion